CD38 and plasma cell myeloma: As shown in Figure 6B, all three CD38 antibodies mediated significant ADCC of L-363 myeloma cells with comparable half-maximal (EC50 #5-CD38-IgG1 = 2.9 pM, EC50 daratumumab = 3.6 pM, EC50 isatuximab = 3.6 pM) and maximum killing (#5-CD38-IgG1 = 45.45 ± 1.31%, daratumumab = 41.97 ± 1.18%, isatuximab = 40.3 ± 0.95%; Figure 6B).